BNP Paribas Financial Markets Has $29.16 Million Stock Position in Tarsus Pharmaceuticals, Inc. $TARS

BNP Paribas Financial Markets lifted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 74.3% in the 4th quarter, HoldingsChannel reports. The fund owned 356,105 shares of the company’s stock after purchasing an additional 151,805 shares during the period. BNP Paribas Financial Markets’ holdings in Tarsus Pharmaceuticals were worth $29,158,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in TARS. Comerica Bank increased its position in shares of Tarsus Pharmaceuticals by 470.0% during the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock worth $70,000 after acquiring an additional 705 shares in the last quarter. Osaic Holdings Inc. increased its position in shares of Tarsus Pharmaceuticals by 779.1% during the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock worth $113,000 after acquiring an additional 2,462 shares in the last quarter. Leonteq Securities AG bought a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth about $164,000. Tower Research Capital LLC TRC increased its position in shares of Tarsus Pharmaceuticals by 220.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock worth $164,000 after acquiring an additional 2,782 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Tarsus Pharmaceuticals by 26.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,063 shares of the company’s stock worth $169,000 after acquiring an additional 431 shares in the last quarter. 90.01% of the stock is owned by institutional investors.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 4,174 shares of the stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $279,658.00. Following the completion of the sale, the insider owned 35,028 shares of the company’s stock, valued at $2,346,876. This represents a 10.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Bobak R. Azamian sold 11,964 shares of the firm’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $801,588.00. Following the completion of the sale, the chief executive officer directly owned 33,421 shares of the company’s stock, valued at approximately $2,239,207. This represents a 26.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 79,391 shares of company stock worth $5,432,035 in the last quarter. 9.64% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Lifesci Capital raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, March 16th. Zacks Research cut shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Oppenheimer assumed coverage on shares of Tarsus Pharmaceuticals in a research note on Friday, April 24th. They set an “outperform” rating and a $98.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $88.00 price target on shares of Tarsus Pharmaceuticals in a research note on Monday, May 4th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $68.00 price target on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Tarsus Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $90.67.

Tarsus Pharmaceuticals Stock Performance

NASDAQ TARS opened at $60.34 on Friday. The company’s 50 day simple moving average is $64.80 and its two-hundred day simple moving average is $70.64. The stock has a market capitalization of $2.60 billion, a PE ratio of -52.93 and a beta of 0.49. Tarsus Pharmaceuticals, Inc. has a 1 year low of $38.51 and a 1 year high of $85.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.74 and a quick ratio of 3.71.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.24. The firm had revenue of $162.05 million for the quarter, compared to analyst estimates of $149.60 million. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.19%. Analysts predict that Tarsus Pharmaceuticals, Inc. will post -0.59 earnings per share for the current fiscal year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro?effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early?stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.